OCULAR THERAPEUTIX, INC Revenue
OCULAR THERAPEUTIX, INC (OCUL) reported Revenue of $13.47 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-03
- OCULAR THERAPEUTIX, INC revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $13.47M, a 0.12% increase year-over-year.
- OCULAR THERAPEUTIX, INC revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $10.79M, a 0.81% increase year-over-year.
- OCULAR THERAPEUTIX, INC revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $13.25M, a 22.43% decline year-over-year.
- OCULAR THERAPEUTIX, INC revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $14.54M, a 5.71% decline year-over-year.
- OCULAR THERAPEUTIX, INC revenue from contract with customer, excluding assessed tax for fiscal 2025 was $51.95M, a 18.47% decline from fiscal 2024.
- OCULAR THERAPEUTIX, INC revenue from contract with customer, excluding assessed tax for fiscal 2024 was $63.72M, a 9.03% increase from fiscal 2023.
- OCULAR THERAPEUTIX, INC revenue from contract with customer, excluding assessed tax for fiscal 2023 was $58.44M, a 13.49% increase from fiscal 2022.
- OCULAR THERAPEUTIX, INC revenue from contract with customer, excluding assessed tax for fiscal 2022 was $51.49M, a 18.32% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $13.47M 10-Q · filed 2026-08-03 | $24.26M 10-Q · filed 2026-08-03 | $37.51M derived: sum of 3 quarters · filed 2026-08-03 | $52.05M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $10.79M 10-Q · filed 2026-05-05 | $24.04M derived: sum of 2 quarters · filed 2026-05-05 | $38.58M derived: sum of 3 quarters · filed 2026-05-05 | $52.04M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $13.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-05 | $27.79M derived: sum of 2 quarters · filed 2026-02-05 | $41.25M derived: sum of 3 quarters · filed 2026-08-03 | $51.95M 10-K · filed 2026-02-05 |
| 2025-09-30 | $14.54M 10-Q · filed 2025-11-04 | $28.00M derived: sum of 2 quarters · filed 2026-08-03 | $38.70M 10-Q · filed 2025-11-04 | $55.78M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $13.46M 10-Q · filed 2026-08-03 | $24.16M 10-Q · filed 2026-08-03 | $41.24M derived: sum of 3 quarters · filed 2026-08-03 | $56.66M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $10.70M 10-Q · filed 2026-05-05 | $27.78M derived: sum of 2 quarters · filed 2026-05-05 | $43.20M derived: sum of 3 quarters · filed 2026-05-05 | $59.65M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $17.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-05 | $32.51M derived: sum of 2 quarters · filed 2026-02-05 | $48.95M derived: sum of 3 quarters · filed 2026-02-05 | $63.72M 10-K · filed 2026-02-05 |
| 2024-09-30 | $15.43M 10-Q · filed 2025-11-04 | $31.87M derived: sum of 2 quarters · filed 2025-11-04 | $46.64M 10-Q · filed 2025-11-04 | $61.44M derived: sum of 4 quarters · filed 2026-02-05 |
| 2024-06-30 | $16.44M 10-Q · filed 2025-08-05 | $31.21M 10-Q · filed 2025-08-05 | $46.02M derived: sum of 3 quarters · filed 2026-02-05 | $61.10M derived: sum of 4 quarters · filed 2026-02-05 |
| 2024-03-31 | $14.77M 10-Q · filed 2025-05-05 | $29.57M derived: sum of 2 quarters · filed 2026-02-05 | $44.66M derived: sum of 3 quarters · filed 2026-02-05 | $59.84M derived: sum of 4 quarters · filed 2026-02-05 |
| 2023-12-31 | $14.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-05 | $29.88M derived: sum of 2 quarters · filed 2026-02-05 | $45.07M derived: sum of 3 quarters · filed 2026-02-05 | $58.44M 10-K · filed 2026-02-05 |
| 2023-09-30 | $15.08M 10-Q · filed 2024-11-14 | $30.27M derived: sum of 2 quarters · filed 2024-11-14 | $43.64M 10-Q · filed 2024-11-14 | $57.72M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $15.19M 10-Q · filed 2024-08-07 | $28.56M 10-Q · filed 2024-08-07 | $42.63M derived: sum of 3 quarters · filed 2025-03-03 | $54.60M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $13.37M 10-Q · filed 2024-05-07 | $27.45M derived: sum of 2 quarters · filed 2025-03-03 | $39.41M derived: sum of 3 quarters · filed 2025-03-03 | $51.68M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $14.07M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $26.04M derived: sum of 2 quarters · filed 2025-03-03 | $38.31M derived: sum of 3 quarters · filed 2025-03-03 | $51.49M 10-K · filed 2025-03-03 |
| 2022-09-30 | $11.96M 10-Q · filed 2023-11-07 | $24.23M derived: sum of 2 quarters · filed 2023-11-07 | $37.42M 10-Q · filed 2023-11-07 | $49.73M derived: sum of 4 quarters · filed 2024-03-11 |
| 2022-06-30 | $12.27M 10-Q · filed 2023-08-07 | $25.45M 10-Q · filed 2023-08-07 | $37.76M derived: sum of 3 quarters · filed 2024-03-11 | $49.91M derived: sum of 4 quarters · filed 2024-03-11 |
| 2022-03-31 | $13.19M 10-Q · filed 2023-05-08 | $25.50M derived: sum of 2 quarters · filed 2024-03-11 | $37.65M derived: sum of 3 quarters · filed 2024-03-11 | $49.37M derived: sum of 4 quarters · filed 2024-03-11 |
| 2021-12-31 | $12.31M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $24.46M derived: sum of 2 quarters · filed 2024-03-11 | $36.18M derived: sum of 3 quarters · filed 2024-03-11 | $43.52M 10-K · filed 2024-03-11 |
| 2021-09-30 | $12.15M 10-Q · filed 2022-11-07 | $23.87M derived: sum of 2 quarters · filed 2022-11-07 | $31.21M 10-Q · filed 2022-11-07 | $38.56M derived: sum of 4 quarters · filed 2023-03-06 |
| 2021-06-30 | $11.72M 10-Q · filed 2022-08-08 | $19.06M 10-Q · filed 2022-08-08 | $26.41M derived: sum of 3 quarters · filed 2023-03-06 | $32.28M derived: sum of 4 quarters · filed 2023-03-06 |
| 2021-03-31 | $7.34M 10-Q · filed 2022-05-09 | $14.69M derived: sum of 2 quarters · filed 2023-03-06 | $20.57M derived: sum of 3 quarters · filed 2023-03-06 | $22.14M derived: sum of 4 quarters · filed 2023-03-06 |
| 2020-12-31 | $7.35M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $13.22M derived: sum of 2 quarters · filed 2023-03-06 | $14.79M derived: sum of 3 quarters · filed 2023-03-06 | $17.40M 10-K · filed 2023-03-06 |
| 2020-09-30 | $5.88M 10-Q · filed 2021-11-08 | $7.45M derived: sum of 2 quarters · filed 2021-11-08 | $10.05M 10-Q · filed 2021-11-08 | $12.31M derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-06-30 | $1.57M 10-Q · filed 2021-08-09 | $4.18M 10-Q · filed 2021-08-09 | $6.43M derived: sum of 3 quarters · filed 2021-08-09 | $7.26M derived: sum of 4 quarters · filed 2021-08-09 |
| 2020-03-31 | $2.61M 10-Q · filed 2021-05-05 | $4.87M derived: sum of 2 quarters · filed 2021-05-05 | $5.69M derived: sum of 3 quarters · filed 2021-05-05 | $6.34M derived: sum of 4 quarters · filed 2021-05-05 |
| 2019-12-31 | $2.26M 10-K · filed 2020-03-12 | $3.08M derived: sum of 2 quarters · filed 2020-11-05 | $3.73M derived: sum of 3 quarters · filed 2020-11-05 | $4.23M 10-K · filed 2022-02-28 |
| 2019-09-30 | $829.00K 10-Q · filed 2020-11-05 | $1.48M derived: sum of 2 quarters · filed 2020-11-05 | $1.97M 10-Q · filed 2020-11-05 | $2.48M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | $650.00K 10-Q · filed 2020-08-07 | $1.14M 10-Q · filed 2020-08-07 | $1.65M derived: sum of 3 quarters · filed 2020-08-07 | $2.14M derived: sum of 4 quarters · filed 2020-08-07 |
| 2019-03-31 | $492.00K 10-Q · filed 2020-05-08 | $996.00K derived: sum of 2 quarters · filed 2020-05-08 | $1.49M derived: sum of 3 quarters · filed 2020-05-08 | $2.14M derived: sum of 4 quarters · filed 2020-05-08 |
| 2018-12-31 | $504.00K 10-K · filed 2020-03-12 | $1.00M derived: sum of 2 quarters · filed 2020-03-12 | $1.65M derived: sum of 3 quarters · filed 2020-03-12 | $1.99M 10-K · filed 2020-03-12 |
| 2018-09-30 | $498.00K 10-K · filed 2020-03-12 | $1.15M derived: sum of 2 quarters · filed 2020-03-12 | $1.49M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $648.00K 10-K · filed 2020-03-12 | $988.00K 10-Q · filed 2019-08-07 | ||
| 2018-03-31 | $340.00K 10-K · filed 2020-03-12 | |||
| 2017-12-31 | $1.92M 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |